Assignee
BEIGENE SWITZERLAND GMBH
CH·18 granted patents·66 pending applications·73 citations·filing 2017–2025
Top patents by PatentIndex Score
84 records- 0198US11186637B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2021·Granted Nov 30, 2021·11 cites·8 claims
- 0298US11142528B2Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulatorsBEIGENE SWITZERLAND GMBH·Filed 2020·Granted Oct 12, 2021·14 cites·19 claims
- 0397US11591340B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Feb 28, 2023·6 cites·27 claims
- 0496US11673951B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2019·Granted Jun 13, 2023·8 cites·11 claims
- 0596US10927117B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2017·Granted Feb 23, 2021·18 cites·6 claims
- 0695US11814389B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Nov 14, 2023·3 cites·8 claims
- 0791US2025059277A1Anti-pd1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 0889US11896596B2Methods of treating B-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Feb 13, 2024·5 cites·28 claims
- 0989US2024409546A1CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 1088US12103931B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Oct 1, 2024·0 cites·16 claims
- 1188US11970500B1Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Apr 30, 2024·0 cites·28 claims
- 1288US2025340560A1SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORSBEIGENE SWITZERLAND GMBH·Filed 2025·Application pending·0 cites
- 1388US2024254128A1SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORSBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 1487US11999743B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Jun 4, 2024·0 cites·27 claims
- 1587US2023303689A1Anti-pd1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 1685US2023242542A1COMPOSITIONS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDEBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 1784US11851437B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Dec 26, 2023·0 cites·29 claims
- 1884US11701357B2Treatment of B cell cancers using a combination comprising Btk inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2017·Granted Jul 18, 2023·4 cites·19 claims
- 1983US11884674B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Jan 30, 2024·0 cites·28 claims
- 2082US11786529B2Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2018·Granted Oct 17, 2023·4 cites·16 claims
- 2180US2022119524A1Anti-pd1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 2279US2024076375A1Anti-TIM-3 Antibodies and Use ThereofBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 2379US2023013862A1SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORSBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 2477US11911386B2Methods of treating B-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Feb 27, 2024·0 cites·30 claims
- 2576US11786531B1Methods of treating B-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Oct 17, 2023·0 cites·30 claims
- 2676US2021130363A1CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 2775US12234286B2Anti-TIGIT antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2021·Granted Feb 25, 2025·0 cites·20 claims
- 2875US2024131030A1Methods of treating b-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 2973US2023149411A1Oral capsule and preparation method thereforBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 3071US12233069B2Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method thereforBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Feb 25, 2025·0 cites·23 claims
- 3169US2023364096A1Use of a combination comprising a btk inhibitor for treating cancersBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 3269US2022251195A1Anti-tigit antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2022·Application pending·0 cites
- 3368US2024366769A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3468US2025059199A1Solid forms of a tyk2 inhibitor, method of preparation, and use thereofBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3568US2025057821A1Methods of treating myeloid malignancies using bcl-2 inhibitorBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3667US2024301051A1Anti-cldn6 antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3766US2025075002A1MUC1 and CD16A Antibodies and Methods of UseBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3866US2024131167A1EGFR Degraders and Associated Methods of UseBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 3966US2024301061A1Anti-cldn6 and anti-cd3 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4066US2024301062A1Anti-cd3 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4165US2025122152A1KAT6 InhibitorsBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4265US2024009197A1Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4364US2025084168A1Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereofBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4464US2025034257A1Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereofBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4563US2024209106A1Anti-cd137 antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4663US2024190989A1Anti-cea and anti-cd137 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4763US2024366770A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4863US2024190990A1Anti-cea antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4962US2024368177A15-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5BEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 5062US2024209113A1Anti-gpc3 and anti-cd137 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
Showing the top 50 of 84 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BEIGENE SWITZERLAND GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →